Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers.

Macha S, Dieterich S, Mattheus M, Seman LJ, Broedl UC, Woerle HJ.

Int J Clin Pharmacol Ther. 2013 Feb;51(2):132-40. doi: 10.5414/CP201794.

PMID:
23253948
2.

A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.

Friedrich C, Metzmann K, Rose P, Mattheus M, Pinnetti S, Woerle HJ.

Clin Ther. 2013 Jan;35(1):A33-42. doi: 10.1016/j.clinthera.2012.12.002.

PMID:
23328275
3.

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.

Brand T, Macha S, Mattheus M, Pinnetti S, Woerle HJ.

Adv Ther. 2012 Oct;29(10):889-99. doi: 10.1007/s12325-012-0055-3. Epub 2012 Oct 1.

PMID:
23054692
4.

Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers.

Macha S, Rose P, Mattheus M, Pinnetti S, Woerle HJ.

Diabetes Obes Metab. 2013 Apr;15(4):316-23. doi: 10.1111/dom.12028. Epub 2012 Nov 22.

PMID:
23094794
5.

Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.

Macha S, Sennewald R, Rose P, Schoene K, Pinnetti S, Woerle HJ, Broedl UC.

Clin Ther. 2013 Mar;35(3):226-35. doi: 10.1016/j.clinthera.2013.02.015.

PMID:
23497760
6.

Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers.

Macha S, Mattheus M, Pinnetti S, Broedl UC, Woerle HJ.

Clin Ther. 2015 Jul 1;37(7):1503-16. doi: 10.1016/j.clinthera.2015.05.002. Epub 2015 Jun 6.

PMID:
26051874
7.

A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.

Vaidyanathan S, Maboudian M, Warren V, Yeh CM, Dieterich HA, Howard D, Dole WP.

Curr Med Res Opin. 2008 Aug;24(8):2313-26. doi: 10.1185/03007990802259354.

PMID:
18786303
8.

Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers.

Macha S, Jungnik A, Hohl K, Hobson D, Salsali A, Woerle HJ.

Int J Clin Pharmacol Ther. 2013 Nov;51(11):873-9.

PMID:
24152604
9.

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers.

Macha S, Lang B, Pinnetti S, Broedl UC.

Int J Clin Pharmacol Ther. 2014 Nov;52(11):973-80. doi: 10.5414/CP202117.

PMID:
25161155
10.

Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.

Macha S, Mattheus M, Pinnetti S, Woerle HJ, Broedl UC.

Clin Drug Investig. 2013 May;33(5):351-7. doi: 10.1007/s40261-013-0068-y.

PMID:
23512637
11.

Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.

Herman GA, Bergman A, Yi B, Kipnes M; Sitagliptin Study 012 Group.

Curr Med Res Opin. 2006 Oct;22(10):1939-47.

PMID:
17022853
12.

Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects.

Shin D, Kim TE, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS.

Curr Med Res Opin. 2012 Jul;28(7):1213-20. doi: 10.1185/03007995.2012.703131. Epub 2012 Jul 2.

PMID:
22697273
13.

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.

Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC.

Diabetes Obes Metab. 2014 Mar;16(3):215-22. doi: 10.1111/dom.12182. Epub 2013 Aug 19.

PMID:
23859488
14.

Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers.

Macha S, Koenen R, Sennewald R, Schöne K, Hummel N, Riedmaier S, Woerle HJ, Salsali A, Broedl UC.

Clin Ther. 2014 Feb 1;36(2):280-90.e1. doi: 10.1016/j.clinthera.2014.01.003. Epub 2014 Feb 1.

PMID:
24491572
15.

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.

Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA.

Curr Med Res Opin. 2009 Aug;25(8):1963-72. doi: 10.1185/03007990903094361.

PMID:
19552619
16.

Pharmacokinetics of fixed-dose combinations of empagliflozin/metformin compared with individual tablets in healthy subjects.

Rojas C, Link J, Meinicke T, Macha S.

Int J Clin Pharmacol Ther. 2016 Apr;54(4):282-92. doi: 10.5414/CP202425.

PMID:
26932302
17.

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.

Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle HJ.

Diabetes Obes Metab. 2013 Dec;15(12):1154-60. doi: 10.1111/dom.12185. Epub 2013 Aug 22.

PMID:
23906374
18.

Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients.

Li J, Klemm K, O'Farrell AM, Guler HP, Cherrington JM, Schwartz S, Boyea T.

Curr Med Res Opin. 2010 Aug;26(8):2003-10. doi: 10.1185/03007995.2010.491266.

PMID:
20583949
19.

Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.

Macha S, Rose P, Mattheus M, Cinca R, Pinnetti S, Broedl UC, Woerle HJ.

Diabetes Obes Metab. 2014 Feb;16(2):118-23. doi: 10.1111/dom.12183. Epub 2013 Aug 19.

PMID:
23859534
20.

Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.

Veltkamp SA, van Dijk J, Collins C, van Bruijnsvoort M, Kadokura T, Smulders RA.

Clin Ther. 2012 Aug;34(8):1761-71. doi: 10.1016/j.clinthera.2012.06.027. Epub 2012 Jul 15.

PMID:
22795925

Supplemental Content

Support Center